{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T09:04:45Z","timestamp":1774343085260,"version":"3.50.1"},"reference-count":37,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2022,10,25]],"date-time":"2022-10-25T00:00:00Z","timestamp":1666656000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Shanghai Municipal Health Committee","award":["20204Y0056"],"award-info":[{"award-number":["20204Y0056"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccines"],"abstract":"<jats:p>With the promotion of mass COVID-19 vaccination in the elimination of the SARS-CoV-2 pandemic, new side effects, including ocular complications, are emerging. In this study, we report on a 62-year-old Chinese man who developed Vogt\u2013Koyanagi\u2013Harada (VKH) disease six days after his third dose of an inactivated COVID-19 vaccine, with a preceding severe headache and tinnitus. His medical history included tuberculosis 20 years prior and hypertension. Systemic prednisone was administered, resulting in completely relieved inflammation and improved visual acuity. Another three and a half months later, the visual acuity of his right eye slightly decreased due to complicated central serous chorioretinopathy (CSC) disease. By gradually replacing prednisone with cyclosporine within 2 months, the subretinal fluid was completely absorbed at the last visit. Steroid-related CSC during the treatment course of VKH disease after COVID-19 vaccination has never been reported before. By reviewing relative literature, we discuss the mechanism of CSC onset in our case and the potential therapeutic strategies. Complicated CSC may develop in the eyes with vaccine-related VKH after steroid treatment. Ophthalmologists should be aware of this condition, carefully distinguish complicated CSC with inflammation relapse, and adjust the medication in a timely manner.<\/jats:p>","DOI":"10.3390\/vaccines10111792","type":"journal-article","created":{"date-parts":[[2022,10,26]],"date-time":"2022-10-26T11:53:51Z","timestamp":1666785231000},"page":"1792","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["COVID-19 Vaccine-Related Vogt\u2013Koyanagi\u2013Harada Disease Complicated by Central Serous Chorioretinopathy during Treatment Course: Case Report and Literature Review"],"prefix":"10.3390","volume":"10","author":[{"given":"Ruyi","family":"Han","sequence":"first","affiliation":[{"name":"Department of Ophthalmology, Eye and ENT Hospital of Fudan University, Shanghai 200031, China"},{"name":"Shanghai Key Laboratory of Visual Impairment and Restoration, Fudan University, Shanghai 200031, China"},{"name":"Key Laboratory of Myopia of National Health Commission, Fudan University, Shanghai 200031, China"},{"name":"Key Laboratory of Myopia, Chinese Academy of Medical Sciences, Shanghai 200031, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gezhi","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Eye and ENT Hospital of Fudan University, Shanghai 200031, China"},{"name":"Shanghai Key Laboratory of Visual Impairment and Restoration, Fudan University, Shanghai 200031, China"},{"name":"Key Laboratory of Myopia of National Health Commission, Fudan University, Shanghai 200031, China"},{"name":"Key Laboratory of Myopia, Chinese Academy of Medical Sciences, Shanghai 200031, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9539-8178","authenticated-orcid":false,"given":"Xinyi","family":"Ding","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Eye and ENT Hospital of Fudan University, Shanghai 200031, China"},{"name":"Shanghai Key Laboratory of Visual Impairment and Restoration, Fudan University, Shanghai 200031, China"},{"name":"Key Laboratory of Myopia of National Health Commission, Fudan University, Shanghai 200031, China"},{"name":"Key Laboratory of Myopia, Chinese Academy of Medical Sciences, Shanghai 200031, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2022,10,25]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1038\/s41577-021-00526-x","article-title":"COVID-19 vaccines: Modes of immune activation and future challenges","volume":"21","author":"Teijaro","year":"2021","journal-title":"Nat. Rev. Immunol."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Lin, W., Wang, J., and Lai, C. (2022). Non-Arteritic Anterior Ischemic Optic Neuropathy Following COVID-19 Vaccination. Vaccines, 10.","DOI":"10.3390\/vaccines10060931"},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Bolletta, E., Iannetta, D., Mastrofilippo, V., de Simone, L., Gozzi, F., Croci, S., Bonacini, M., Belloni, L., Zerbini, A., and Adani, C. (2021). Uveitis and Other Ocular Complications Following COVID-19 Vaccination. J. Clin. Med., 10.","DOI":"10.3390\/jcm10245960"},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Ding, X., and Chang, Q. (2022). Probable Vogt-Koyanagi-Harada Disease after COVID-19 Vaccination: Case Report and Literature Review. Vaccines, 10.","DOI":"10.3390\/vaccines10050783"},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Haseeb, A., Solyman, O., Abushanab, M., Abo Obaia, A., and Elhusseiny, A. (2022). Ocular Complications Following Vaccination for COVID-19: A One-Year Retrospective. Vaccines, 10.","DOI":"10.3390\/vaccines10020342"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/S0002-9394(01)00925-4","article-title":"Revised diagnostic criteria for Vogt-Koyanagi-Harada disease: Report of an international committee on nomenclature","volume":"131","author":"Read","year":"2001","journal-title":"Am. J. Ophthalmol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1080\/09273948.2021.1974492","article-title":"Vogt-Koyanagi-Harada Disease Associated with COVID-19 mRNA Vaccine","volume":"29","author":"Koong","year":"2021","journal-title":"Ocul. Immunol. Inflamm."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"321","DOI":"10.4103\/ijo.IJO_2589_21","article-title":"Harada-like syndrome post-Covishield vaccination: A rare adverse effect","volume":"70","author":"Reddy","year":"2022","journal-title":"Indian J. Ophthalmol."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"De Domingo, B., L\u00f3pez, M., Lopez-Valladares, M., Ortegon-Aguilar, E., Sope\u00f1a-Perez-Arg\u00fcelles, B., and Gonzalez, F. (2022). Vogt-Koyanagi-Harada Disease Exacerbation Associated with COVID-19 Vaccine. Cells, 11.","DOI":"10.3390\/cells11061012"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"482","DOI":"10.3390\/vaccines10030482","article-title":"Ocular Adverse Events after Inactivated COVID-19 Vaccination in Xiamen","volume":"10","author":"Chen","year":"2022","journal-title":"Vaccines"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/clpt.1981.154","article-title":"A method for estimating the probability of adverse drug reactions","volume":"30","author":"Naranjo","year":"1981","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/s12348-021-00251-5","article-title":"Reactivation of Vogt-Koyanagi-Harada disease under control for more than 6\u2009years, following anti-SARS-CoV-2 vaccination","volume":"11","author":"Papasavvas","year":"2021","journal-title":"J. Ophthalmic Inflamm. Infect."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s40942-021-00319-3","article-title":"Vogt-Koyanagi-Harada Syndrome following COVID-19 and ChAdOx1 nCoV-19 (AZD1222) vaccine","volume":"7","author":"Saraceno","year":"2021","journal-title":"Int. J. Retin. Vitr."},{"key":"ref_14","first-page":"150","article-title":"Autoimmune\/Inflammatory Syndrome Induced by Adjuvants and Thyroid Autoimmunity","volume":"7","author":"Watad","year":"2016","journal-title":"Front. Endocrinol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"3420","DOI":"10.4103\/ijo.IJO_861_22","article-title":"Bilateral multifocal choroiditis with disc edema in a 15-year-old girl following COVID-19 vaccination","volume":"70","author":"Kakarla","year":"2022","journal-title":"Indian J. Ophthalmol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.preteyeres.2016.02.002","article-title":"Vogt-Koyanagi-Harada disease: Novel insights into pathophysiology, diagnosis and treatment","volume":"52","author":"Du","year":"2016","journal-title":"Prog. Retin. Eye Res."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/eye.2008.89","article-title":"Effects of the duration of initial oral corticosteroid treatment on the recurrence of inflammation in Vogt-Koyanagi-Harada disease","volume":"23","author":"Lai","year":"2009","journal-title":"Eye"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.ajo.2006.02.049","article-title":"Evaluation of the effect on outcomes of the route of administration of corticosteroids in acute Vogt-Koyanagi-Harada disease","volume":"142","author":"Read","year":"2006","journal-title":"Am. J. Ophthalmol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"60s6","DOI":"10.1016\/j.ophtha.2006.07.040","article-title":"Kijlstra A Clinical characteristics of Vogt-Koyanagi-Harada syndrome in Chinese patients","volume":"114","author":"Yang","year":"2007","journal-title":"Ophthalmology"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1080\/09273948.2021.1949478","article-title":"Palestine A Panuveitis following Vaccination for COVID-19","volume":"29","author":"Mudie","year":"2021","journal-title":"Ocul. Immunol. Inflamm."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.clim.2008.12.007","article-title":"Inhibitory effect of Cyclosporin A and corticosteroids on the production of IFN-gamma and IL-17 by T cells in Vogt-Koyanagi-Harada syndrome","volume":"131","author":"Liu","year":"2009","journal-title":"Clin. Immunol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.ajo.2020.07.036","article-title":"Vogt-Koyanagi-Harada Disease Managed with Immunomodulatory Therapy Within 3 Months of Disease Onset","volume":"220","author":"Oo","year":"2020","journal-title":"Am. J. Ophthalmol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"e475","DOI":"10.1111\/aos.12648","article-title":"Earlier immunomodulatory treatment is associated with better visual outcomes in a subset of patients with Vogt-Koyanagi-Harada disease","volume":"93","author":"Urzua","year":"2015","journal-title":"Acta Ophthalmol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1080\/09273940500536766","article-title":"Immunomodulatory therapy for Vogt-Koyanagi-Harada patients as first-line therapy","volume":"14","author":"Paredes","year":"2006","journal-title":"Ocul. Immunol. Inflamm."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1136\/bjo.68.5.329","article-title":"Central serous chorioretinopathy complicating systemic corticosteroid treatment","volume":"68","author":"Wakakura","year":"1984","journal-title":"Br. J. Ophthalmol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/S0161-6420(95)30960-8","article-title":"Bilateral bullous exudative retinal detachment complicating idiopathic central serous chorioretinopathy during systemic corticosteroid therapy","volume":"102","author":"Gass","year":"1995","journal-title":"Ophthalmology"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1177\/112067219700700317","article-title":"Central serous chorioretinopathy complicating systemic corticosteroid therapy","volume":"7","year":"1997","journal-title":"Eur. J. Ophthalmol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.4103\/ijo.IJO_2306_21","article-title":"Acute central serous chorioretinopathy following subconjunctival triamcinolone acetonide injection in cataract surgery (less drop approach)\u2014A case series","volume":"70","author":"Aravind","year":"2022","journal-title":"Indian J. Ophthalmol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1111\/ceo.13807","article-title":"Central serous chorioretinopathy secondary to subtenon triamcinolone injection: A new hypothesis for the mechanism","volume":"48","author":"Dhanji","year":"2020","journal-title":"Clin. Exp. Ophthalmol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1186\/s13256-019-2143-3","article-title":"Central serous retinopathy associated with topical oral corticosteroid use: A case report","volume":"13","author":"Young","year":"2019","journal-title":"J. Med. Case Rep."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"2672","DOI":"10.1172\/JCI61427","article-title":"Mineralocorticoid receptor is involved in rat and human ocular chorioretinopathy","volume":"122","author":"Zhao","year":"2012","journal-title":"J. Clin. Investig."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1167\/iovs.13-12854","article-title":"Changes in choroidal thickness after systemic administration of high-dose corticosteroids: A pilot study","volume":"55","author":"Han","year":"2014","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"100770","DOI":"10.1016\/j.preteyeres.2019.07.003","article-title":"Central serous chorioretinopathy: Towards an evidence-based treatment guideline","volume":"73","author":"Yzer","year":"2019","journal-title":"Prog. Retin. Eye Res."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.ajo.2009.11.017","article-title":"Central serous chorioretinopathy: A personal perspective","volume":"149","author":"Yannuzzi","year":"2010","journal-title":"Am. J. Ophthalmol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1016\/j.ophtha.2008.04.014","article-title":"Half-dose verteporfin photodynamic therapy for acute central serous chorioretinopathy: One-year results of a randomized controlled trial","volume":"115","author":"Chan","year":"2008","journal-title":"Ophthalmology"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1111\/cxo.12818","article-title":"Subthreshold diode micropulse laser versus observation in acute central serous chorioretinopathy","volume":"102","author":"Arora","year":"2019","journal-title":"Clin. Exp. Optom."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1097\/IAE.0000000000000748","article-title":"Central serous chorioretinopathy treated with mineralocorticoid antagonists: A one-year pilot study","volume":"36","author":"Ghadiali","year":"2016","journal-title":"Retina"}],"container-title":["Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-393X\/10\/11\/1792\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T01:02:20Z","timestamp":1760144540000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-393X\/10\/11\/1792"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,25]]},"references-count":37,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2022,11]]}},"alternative-id":["vaccines10111792"],"URL":"https:\/\/doi.org\/10.3390\/vaccines10111792","relation":{},"ISSN":["2076-393X"],"issn-type":[{"value":"2076-393X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,25]]}}}